CoChat

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Patients with diabetes mellitus inject insulin in different regions of the body. This study investigated the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a new-generation once-daily basal insulin with an ultra-long duration of action, after subcutaneous (SC) administration in different injection regions. METHODS: In this study, 20 healthy subjects received single SC doses of IDeg (0.4 U/kg; separated by 13-21 days) in the thigh, abdomen and deltoid in a randomised, open-label, single-centre, single-dose, complete crossover trial. Each dose was followed by a 24-h euglycaemic clamp and 120-h pharmacokinetic blood sampling. The obtained pharmacokinetic/pharmacodynamic profiles were extrapolated to steady state by simulation using a pharmacokinetic/pharmacodynamic model. RESULTS: Total IDeg exposure [area under the IDeg serum concentration-time curve 0-120 h after a single dose (AUCIDeg,0-120h,SD)] and maximum serum concentration [maximum IDeg serum concentration after a single dose (C max,IDeg,SD)] were higher (6-7 and 23-27 %, respectively) following a single SC dose in the deltoid or abdomen, compared with the thigh, as also observed with other insulin preparations. No statistical difference was observed in these measures between deltoid and abdominal administration. No pronounced differences were observed in the glucose-lowering effect of IDeg [area under the glucose infusion rate (GIR) curve 0-24 h after a single dose (AUCGIR,0-24h,SD) and maximum GIR after a single dose (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0-24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively). Simulated mean steady-state pharmacokinetic and pharmacodynamic profiles supported a flat and stable IDeg exposure and effect regardless of injection region, with comparable total glucose-lowering effects [area under the GIR curve at steady state (AUCGIR,τ,SS)] between the thigh, abdomen and deltoid. CONCLUSIONS: These findings support administering IDeg SC in the thigh, upper arm or abdominal wall without affecting IDeg absorption or effect at steady state.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40261-014-0218-x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 a Mean 24-h pharmacokinetic profiles after a single subcutaneous dose of insulin degludec (0.4 U/kg), administered in the thigh, abdomen or deltoid. b Mean 24-h pharmacokinetic profiles when simulated to steady state after once-daily subcutaneous administration of insulin degludec (0.4 U/kg) in the thigh, abdomen or deltoid. Because there was no difference in total exposure (AUCIDeg,0–120h,SD) between the deltoid and abdomen after a single dose, the pharmacokinetic profiles for these two injection regions are superimposed in the steady-state simulation. AUC IDeg,0–120h,SD area under the insulin degludec serum concentration–time curve 0–120 h after a single dose, conc. concentration, IDeg insulin degludec
Fig. 1 a Mean 24-h pharmacokinetic profiles after a single subcutaneous dose of insulin degludec (0.4 U/kg), administered in the thigh, abdomen or deltoid. b Mean 24-h pharmacokinetic profiles when simulated to steady state after once-daily subcutaneous administration of insulin degludec (0.4 U/kg) in the thigh, abdomen or deltoid. Because there was no difference in total exposure (AUCIDeg,0–120h,SD) between the deltoid and abdomen after a single dose, the pharmacokinetic profiles for these two injection regions are superimposed in the steady-state simulation. AUC IDeg,0–120h,SD area under the insulin degludec serum concentration–time curve 0–120 h after a single dose, conc. concentration, IDeg insulin degludecCC BY-NC · PubMed Central
Fig. 2 a Mean 24-h pharmacodynamic profiles after a single subcutaneous dose of insulin degludec (0.4 U/kg), administered in the thigh, abdomen or deltoid. b Mean 24-h pharmacodynamic profiles when simulated to steady-state after once-daily subcutaneous administration of insulin degludec (0.4 U/kg) in the thigh, abdomen or deltoid. Because there was no difference in total exposure (AUCIDeg,0–120h,SD) between the deltoid and abdomen after a single dose, the pharmacodynamic profiles for these two injection regions are superimposed in the steady-state simulation. AUC IDeg,0–120h,SD area under the insulin degludec serum concentration–time curve 0–120 h after a single dose, GIR glucose infusion rate
Fig. 2 a Mean 24-h pharmacodynamic profiles after a single subcutaneous dose of insulin degludec (0.4 U/kg), administered in the thigh, abdomen or deltoid. b Mean 24-h pharmacodynamic profiles when simulated to steady-state after once-daily subcutaneous administration of insulin degludec (0.4 U/kg) in the thigh, abdomen or deltoid. Because there was no difference in total exposure (AUCIDeg,0–120h,SD) between the deltoid and abdomen after a single dose, the pharmacodynamic profiles for these two injection regions are superimposed in the steady-state simulation. AUC IDeg,0–120h,SD area under the insulin degludec serum concentration–time curve 0–120 h after a single dose, GIR glucose infusion rateCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 2

  1. Kurtzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54:S426.
  2. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: twofold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia. 2011;54:S425.

Cited by

See all 44

Metadata

Authors
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T.
Affiliations
  • Profil Institute for Metabolic Research (DE)
  • Novo Nordisk (Denmark) (DK)
Corresponding author
Nosek, Leszek
Venue
Clinical Drug Investigation
Published
2014-08-16
Volume
34
Issue
9
Pages
673-679
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W2099438726
Cited by
42
References
20
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 2 · 2015: 4 · 2014: 1
FWCI
2.68
Type
journal article
Language
en
Open access
Locations
  • Clinical Drug Investigation (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
Keywords
insulin degludec, subcutaneous injection site, basal insulin, pharmacokinetics, pharmacodynamics, glucose-lowering effect, insulin absorption, euglycaemic clamp, thigh, deltoid muscle, abdomen, diabetes mellitus, ultra-long-acting insulin
MeSH terms
Adult, Blood Glucose, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Models, Biological, Glucose Clamp Technique, Cross-Over Studies, Area Under Curve, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. https://app.cochat.ai/papers/10.1007/s40261-014-0218-x
The paper
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014). Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clinical Drug Investigation. https://doi.org/10.1007/s40261-014-0218-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.